|
Home | Issues | eMJA shop | Classifieds | Contact | More... | Topics | Search | Login | Buy full access |
→ Contents list for this issue
→ More articles on Pharmacology
→ More articles on Paediatrics
→ More articles on Infectious diseases
→ Search PubMed for related articles
Click to Login
Hide the Login Box
To the Editor: Isoniazid is used extensively for the treatment of active and latent tuberculosis (TB). It is generally well tolerated by children, and hypersensitivity reactions resulting in skin rash and requiring cessation of treatment are rarely reported in this age group.1,2
Login or register to purchase access to the full article
|
|
Home | Issues | eMJA shop | Terms of use | Classifieds | More... | Contact | Topics | Search |
©The Medical Journal of Australia 2009 www.mja.com.au PRINT ISSN: 0025-729X ONLINE ISSN: 1326-5377